All stock lists
Oruka Therapeutics, Inc. (NASDAQ:ORKA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
92.89+12.74 (+15.90%)
Insider Score
––Not scored
ORKA Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ORKA analyst forecast
ORKA analyst consensus
Moderate Buy4 ratings
Buy 4 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
ORKA 12-month price target
No published price targets in the last 12 months.
Best analysts covering ORKA
- HC Wainwright & Co.100%success rate · 6 calls
- BTIG100%success rate · 2 calls
- Wedbush100%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
ORKA analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | BTIG | Buy | — | — | Reiterated | 2026-10-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-24 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-09-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-03 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-08-11 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-11 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-03 |
| — | BTIG | Buy | — | — | Reiterated | 2026-07-13 |
| — | UBS | Buy | — | — | Reiterated | 2026-07-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-18 |
| — | BTIG | Buy | — | — | Reiterated | 2026-05-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-04-29 |
| — | UBS | Buy | — | — | Reiterated | 2026-04-28 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-28 |
| — | BTIG | Buy | — | — | Reiterated | 2026-04-27 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-04-15 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-04-13 |
| — | BTIG | Buy | — | — | Reiterated | 2026-04-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-04-13 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-04-09 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-04-07 |
| — | UBS | Buy | — | — | Reiterated | 2026-04-06 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-04-06 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-03-16 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-03-13 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-03-13 |
| — | Stifel | Buy | — | — | Reiterated | 2026-03-13 |
| — | BTIG | Buy | — | — | Reiterated | 2026-03-13 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-03-13 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-01-13 |
| — | BTIG | Buy | — | — | Reiterated | 2026-01-12 |
| — | BTIG | Buy | — | — | Reiterated | 2025-11-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-27 |
| — | BTIG | Buy | — | — | Reiterated | 2025-09-29 |
| — | Clear Street | Buy | — | — | Reiterated | 2025-09-17 |
| — | BTIG | Buy | — | — | Reiterated | 2025-09-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-07-23 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-05-15 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-25 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-31 |
ORKA earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | -0.61 | -0.45 | $0 | $0 |
| 2026-05-13 | -0.55 | -0.48 | $0 | $0 |
| 2026-08-10 | -0.51 | -0.55 | $0 | $0 |
| 2026-11-11 | -0.60 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.